NDAORALFOR SUSPENSIONPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Intelligence
8/8 — Comprehensive
Priority Review
EMEND (aprepitant) by Merck & Co. is neurokinin 1 antagonists [moa]. Approved for older for the prevention of: acute, delayed nausea, vomiting associated with initial and 7 more indications. First approved in 2015.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Indications (10)
Worked on EMEND at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.